DocMorris launches approx. CHF 200 million Convertible Bonds due 2029 – Biotech Investments

In a close­ly watched read­out, Bio­haven’s au­toim­mune dis­ease treat­ment led to a 37% re­duc­tion on av­er­age in lev­els of harm­ful an­ti­bod­ies at the high­est re­port­ed

The new class of GLP-1 drug brands is dri­ving di­a­betes and weight loss pre­scrip­tion drug ad­ver­tis­ing spend­ing, push­ing the com­bined cat­e­go­ry to more than $1

Light Horse pursues a function-first approach with its genetic editing-based platform. Image credit: Shutterstock/ Hyejin Kang. Light Horse Therapeutics has galloped on to the biotech